MSACL testimonial from Dr. Michael Lutz
20 Nov 2023
In this video, Thermo Fisher Scientific presents a testimonial from Dr. Michael Lutz, senior advisor at Osteolabs, a diagnostic company specializing in clinical assays for metabolic bone disorders. Dr. Lutz discusses how the use of inductively coupled plasma mass spectrometry (ICP-MS) methods developed by Osteolabs will impact over 1 billion patients with metabolic bone diseases around the world.
About the company
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
